Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study.
Jurij HanželErwin DreesenSéverine VermeireMark LöwenbergFrank HoentjenPeter BossuytEsmé ClasquinFilip J BaertGeert R D'HaensRon MathôtPublished in: Inflammatory bowel diseases (2021)
Model-informed dosing of vedolizumab in CD provides a foundation for future research aiming to maximize endoscopic remission rates.